Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight

This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by increase in bodyweight. Data from the RADAR‐JAPAN studies were used, evaluating the effect of 0.75 or 1.25 mg/d...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes Obes Metab
Main Authors: Koomen, Jeroen V., Stevens, Jasper, Mostafa, Nael M., Parving, Hans‐Henrik, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2018
Subjects:
Brief Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6055665/
https://ncbi.nlm.nih.gov/pubmed/29603851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13312
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items